David Pyott Net Worth

The estimated Net Worth of David E I Pyott is at least $9.01 Milione dollars as of 24 June 2024. Mr. Pyott owns over 32,450 units of Alnylam Pharmaceuticals Inc stock worth over $8,534,599 and over the last 21 years he sold ALNY stock worth over $0. In addition, he makes $470,707 as Independent Director at Alnylam Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Pyott ALNY stock SEC Form 4 insiders trading

David has made over 28 trades of the Alnylam Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 32,450 units of ALNY stock worth $2,620,662 on 24 June 2024.

The largest trade he's ever made was exercising 32,450 units of Alnylam Pharmaceuticals Inc stock on 24 June 2024 worth over $2,620,662. On average, David trades about 1,283 units every 38 days since 2003. As of 24 June 2024 he still owns at least 32,586 units of Alnylam Pharmaceuticals Inc stock.

You can see the complete history of Mr. Pyott stock trades at the bottom of the page.

David Pyott biography

David E.I. Pyott is an Independent Director of the Alnylam Pharmaceuticals, Inc. Mr. Pyott served as the Chief Executive Officer of Allergan, Inc., a global specialty pharmaceutical and medical device company, from January 1998 to March 2015 and as the Chair of Allergan’s board of directors from March 2001 until March 2015. Prior to Allergan, Mr. Pyott served as the Head of the Novartis Nutrition Division and as a member of the Executive Committee of Switzerland-based Novartis AG. Mr. Pyott also serves as the lead independent director at Avery Dennison Corporation, a director of BioMarin Pharmaceutical Inc. and a member of the Supervisory Board of Royal Philips in the Netherlands. Mr. Pyott formerly served as a director of Edwards Lifesciences Corporation.

What is the salary of David Pyott?

As the Independent Director of Alnylam Pharmaceuticals Inc, the total compensation of David Pyott at Alnylam Pharmaceuticals Inc is $470,707. There are 17 executives at Alnylam Pharmaceuticals Inc getting paid more, with John Maraganore having the highest compensation of $7,317,860.

How old is David Pyott?

David Pyott is 67, he's been the Independent Director of Alnylam Pharmaceuticals Inc since 2015. There are 2 older and 17 younger executives at Alnylam Pharmaceuticals Inc. The oldest executive at Alnylam Pharmaceuticals Inc is Phillip Sharp, 75, who is the Independent Director.

What's David Pyott's mailing address?

David's mailing address filed with the SEC is 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142.

Insiders trading at Alnylam Pharmaceuticals Inc

Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal e Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.

What does Alnylam Pharmaceuticals Inc do?

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Complete history of Mr. Pyott stock trades at Alnylam Pharmaceuticals Inc, Biomarin Pharmaceutical, Avery Dennison, Edwards Lifesciences Corp e Pliant Therapeutics

Alnylam Pharmaceuticals Inc executives and stock owners

Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• John Maraganore,
  Chief Executive Officer, Director
• Jeffrey Poulton,
  Chief Financial Officer, Executive Vice President
• Laurie Keating,
  Executive Vice President, Chief Legal Officer, Secretary
• Yvonne Greenstreet,
  President, Chief Operating Officer
• Akshay Vaishnaw,
  President - Research and Development
• Dr. John M. Maraganore M.D., Ph.D.,
  CEO & Exec. Director
• Margaret Hamburg,
  Independent Director
• Dr. Yvonne L. Greenstreet M.B.A., MBA, MBChB,
  Pres, COO & Director
• Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA,
  Pres & COO
• Dr. Akshay K. Vaishnaw,
  Pres of R&D
• Jeffrey V. Poulton M.B.A.,
  CFO & Exec. VP
• Laurie Bartlett Keating J.D.,
  Exec. VP, Chief Legal Officer & Sec.
• Michael Bonney,
  Independent Chairman of the Board
• Phillip Sharp,
  Independent Director
• Marsha Fanucci,
  Independent Director
• Amy Schulman,
  Independent Director
• Steven Paul,
  Independent Director
• Colleen Reitan,
  Independent Director
• David Pyott,
  Independent Director
• Dennis Ausiello,
  Independent Director
• Michael W. Bonney B.A.,
  Exec. Chairman
• Olivier Brandicourt,
  Director
• Kevin Fitzgerald,
  Senior Vice President, Chief Scientific Officer
• Kelley Boucher,
  Chief Human Resource Officer, Senior Vice President
• Arianna Greco,
  Interim Chief Legal officer
• Mark Baglin,
  VP of Global Marketing
• Agnieszka Gallagher,
  Chief Ethics & Compliance Officer
• Christine Regan Lindenboom,
  Sr. VP of Investor Relations & Corp. Communications
• Dr. Alfred W. Boyle Ph.D.,
  Chief Technical Operations & Quality Officer
• David Alexandre C Gros,
  SVP, Chief Business Officer
• Kevin P Starr,
  Director
• Paul Schimmel,
  Director
• Sanofi,
  10% owner
• Michael Mason,
  VP, Finance and Treasurer
• John K Clarke,
  Director
• Barry E Greene,
  President
• Manmeet Singh Soni,
  Chief Financial Officer
• Carolyn R Bertozzi,
  Director
• Pushkal Garg,
  CMO & EVP Dev & Med Affairs
• Peter N Kellogg,
  Director
• Venture Management Co Iii L...,
  10% owner
• Victor J Dzau,
  Director
• Agnovartis Pharma Ag Novartis,
  
• Venture Management Co Iii L...,
  
• Peter Barrett,
  Director
• Christoph H Westphal,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Venture Management Co Iii L...,
  
• Ii Lp Chp,
  10% owner
• Kenneth S Koblan,
  Chief Scientific Officer
• Laurence Reid,
  SVP, Chief Business Officer
• Vicki L Sato,
  Director
• Management Ltd Abingworth,
  10% owner
• John A Jr Schmidt,
  SVP, Chief Scientific Officer
• Patricia L Allen,
  VP Finance and Treasurer
• Venture Fund V Lpatlas Vent...,
  
• John E Berriman,
  Director
• Vincent J Miles,
  Senior VP Business Development
• James L Vincent,
  Director
• Venture Fund V Lpatlas Vent...,
  
• Edward M Scolnick,
  Director
• Tolga Tanguler,
  EVP, Chief Commercial Officer
• Charles Elliott Sigal,
  Director